Who Pays for Drug Quality?
This study examines how pharmaceutical costs for higher quality drugs are shared between insurers and consumers. Who bears these costs has important implications for patient access to better drugs, and for differences in access to higher quality pharmaceuticals. We investigate these issues using data from two large drug product classes: non-steroidal anti-inflammatory drugs (NSAIDs) and antidepressants. We find that insurers shift the drug costs associated with higher quality onto consumers for antidepressants but share in the costs of higher quality for NSAIDs. This suggests that patients’ cost burden, hence access, to higher quality drugs may vary across drug product classes.
Volume (Year): 36 (2010)
Issue (Month): 2 (Spring)
|Contact details of provider:|| Web page: http://www.palgrave-journals.com/|
|Order Information:|| Postal: Palgrave Macmillan Journals, Subscription Department, Houndmills, Basingstoke, Hampshire RG21 6XS, UK|
Web: http://www.palgrave-journals.com/pal/subscribe/index.html Email:
When requesting a correction, please mention this item's handle: RePEc:pal:easeco:v:36:y:2010:i:2:p:239-254. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Daniel Foley)
If references are entirely missing, you can add them using this form.